共 12 条
[1]
Metabolomic studies of human gastric cancer:Review[J] Naresh Doni Jayavelu;Nadav S Bar; World Journal of Gastroenterology 2014,
[2]
Treatment options in patients with metastatic gastric cancer:Current status and future perspectives[J] Ahmet Bilici; World Journal of Gastroenterology 2014,
[3]
An updated review of gastric cancer in the next-generation sequencing era:Insights from bench to bedside and vice versa[J] Hiroyuki Yamamoto;Yoshiyuki Watanabe;Tadateru Maehata;Ryo Morita;Yoshihito Yoshida;Ritsuko Oikawa;Shinya Ishigooka;Shun-ichiro Ozawa;Yasumasa Matsuo;Kosuke Hosoya;Masaki Yamashita;Hiroaki Taniguchi;Katsuhiko Nosho;Hiromu Suzuki;Hiroshi Yasuda;Yasuhisa Shinomura;Fumio Itoh; World Journal of Gastroenterology 2014,
[4]
Targeted therapy in gastric cancer:Personalizing cancer treatment based on patient genome[J] Sun Min Lim;Jae Yun Lim;Jae Yong Cho; World Journal of Gastroenterology 2014,
[5]
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international; randomised; multicentre; placebo-controlled; phase 3 trial[J] Charles S Fuchs;Jiri Tomasek;Cho Jae Yong;Filip Dumitru;Rodolfo Passalacqua;Chanchal Goswami;Howard Safran;Lucas Vieira dos Santos;Giuseppe Aprile;David R Ferry;Bohuslav Melichar;Mustapha Tehfe;Eldar Topuzov;John Raymond Zalcberg;Ian Chau;William Campbell;Choondal Sivanandan;Joanna Pikiel;Minori Kos
[6]
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised; open-label phase 3 trial[J] Florian Lordick;Yoon-Koo Kang;Hyun-Cheol Chung;Pamela Salman;Sang Cheul Oh;György Bodoky;Galina Kurteva;Constantin Volovat;Vladimir M Moiseyenko;Vera Gorbunova;Joon Oh Park;Akira Sawaki;Ilhan Celik;Heiko Götte;Helena Melezínková;Markus Moehler Lancet Oncology 2013,
[7]
Immunohistochemical expression of mTOR negatively correlates with PTENexpression in gastric carcinoma[J] Min Li;Huawen Sun;Lujun Song;Xiaodong Gao;Wenju Chang;Xinyu Qin Oncology Letters 2012,
[8]
A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab; Lapatinib; an Anthracycline; a Taxane; and Capecitabine[J] Ian E. Krop;Patricia LoRusso;Kathy D. Miller;Shanu Modi;Denise Yardley;Gladys Rodriguez;Ellie Guardino;Michael Lu;Maoxia Zheng;Sandhya Girish;Lukas Amler;Eric P. Winer;Hope S. Rugo Journal of Clinical Oncology 2012,
[9]
Intratumoral Heterogeneity Determines Discordant Results of Diagnostic Tests for Human Epidermal Growth Factor Receptor (HER) 2 in Gastric Cancer Specimens[J] Jiyuan Yang;Hesheng Luo;Yan Li;Junchuan Li;Zhiqiang Cai;Xiaoyan Su;Danqing Dai;Wei Du;Tingxuan Chen;Ming Chen Cell Biochemistry and Biophysics 2012,
[10]
Impact of MET amplification on gastric cancer: Possible roles as a novelprognostic marker and a potential therapeutic target[J] Jeeyun Lee;Jin Seo;Hyun Jun;Chang-Seok Ki;Se Park;Young Park;Ho Lim;Min Choi;Jae Bae;Tae Sohn;Jae Noh;Sung Kim;Hey-Lim Jang;Ji-Youn Kim;Kyoung-Mee Kim;Won Kang;Joon Park Oncology Reports 2011,